AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER Drug Patent Profile

Which patents cover Aminosyn Ii 5% W/ Electrolytes In Dextrose 25% W/ Calcium In Plastic Container, and when can generic versions of Aminosyn Ii 5% W/ Electrolytes In Dextrose 25% W/ Calcium In Plastic Container launch?

Aminosyn Ii 5% W/ Electrolytes In Dextrose 25% W/ Calcium In Plastic Container is a drug marketed by Abbott and Hospira Inc and is included in two NDAs.

The generic ingredient in AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER is amino acids; calcium chloride; dextrose; magnesium chloride; potassium chloride; potassium phosphate, dibasic; sodium chloride. There are three hundred and fifty drug master file entries for this compound. Additional details are available on the amino acids; calcium chloride; dextrose; magnesium chloride; potassium chloride; potassium phosphate, dibasic; sodium chloride profile page.

Summary for AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

US Patents:	0
Applicants:	2
NDAs:	2
DailyMed Link:	AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER at DailyMed

US Patents and Regulatory Information for AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbott	AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER	amino acids; calcium chloride; dextrose; magnesium chloride; potassium chloride; potassium phosphate, dibasic; sodium chloride	INJECTABLE;INJECTION	019714-003	Sep 12, 1988		DISCN	No	No
Hospira Inc	AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER	amino acids; calcium chloride; dextrose; magnesium chloride; potassium chloride; potassium phosphate, dibasic; sodium chloride	INJECTABLE;INJECTION	019683-004	Nov 7, 1988		DISCN	No	No

AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER Market Analysis and Financial Projection

Last updated: February 15, 2026

Market Dynamics and Financial Trajectory for AMINOSYN II 5% with Electrolytes

Market Overview

AMINOSYN II 5% with electrolytes in dextrose 25% with calcium is a parenteral amino acid solution marketed primarily for nutritional support in hospitalized patients. The drug falls within the broader amino acid infusion market, which supports patients with malnutrition, critical illness, or gastrointestinal dysfunction.

Key Market Drivers

• Increasing Prevalence of Malnutrition: Hospitals report rising cases of malnutrition among chronic and critically ill patients, driving demand for total parenteral nutrition (TPN) solutions like AMINOSYN II.
• Growing Use in Critical Care: The expanding ICU patient base, especially in aging populations, elevates the need for intravenous nutritional supplements.
• Shift Toward Customizable Nutritional Solutions: Hospitals prefer formulations offering electrolyte compatibility with amino acids, enhancing clinical outcomes.

Competitive Landscape

Major players include Baxter International, Hospira (Pfizer), and Fresenius Kabi. These companies operate extensive manufacturing capacity, with AMINOSYN II competing on formulation stability, electrolyte balance, and safety profile. The pharmaceutical industry trend is toward biosimilar and generic amino acid solutions, pressuring pricing and margins.

Regulatory Environment

AMINOSYN II’s approvals in key markets like the US (FDA clearance) and Europe (EMA approval) facilitate market entry. Stringent regulations govern labeling, stability, and compounding standards. Registration delays or non-compliance pose risks, impacting supply and revenue.

Pricing and Reimbursement Considerations

Reimbursement models in the US (Medicare/Medicaid) and Europe influence sales. The drug's pricing is affected by market competition, formulary inclusion, and hospital procurement strategies. Reimbursement rates vary regionally, impacting profitability.

Market Size and Forecast

• Global Parenteral Nutrition Market Size: Estimated at USD 9 billion in 2022, with an annual growth rate of about 6% through 2027 [1].
• Amino Acid Solutions Segment: Constitutes approximately 35-45% of the total market; projected to grow tandem with inpatient nutrition needs.
• Expected Revenue Trajectory: For AMINOSYN II, sales are projected to increase at 4-6% annually based on hospital adoption rates, patient volume, and emerging clinical evidence supporting its electrolyte composition.

Financial Outlook

• Revenue Potential: For a mid-sized manufacturer, annual sales could reach USD 100-200 million, considering hospital demand, market share, and pricing strategies.
• Cost Structure: R&D costs are fixed, with significant expenses in manufacturing quality, compliance, and distribution logistics. Gross margins generally range from 40% to 60%, depending on scale and efficiency.
• Profitability Factors: Volume growth, procurement discounts, regulatory approvals, and formulary access influence profit margins. Increased competition could compress prices, reducing margins over time.

Risks and Opportunities

• Supply Chain Disruptions: Ingredient shortages, manufacturing delays, or regulatory hurdles could impact supply.
• Market Penetration: Partnership with hospital groups and inclusion in clinical guidelines boost adoption.
• Innovation: Development of similar or improved formulations, such as amino acids with enhanced stability or targeted nutrient content, can expand market share.

Summary:

AMINOSYN II 5% with electrolytes in dextrose 25% with calcium operates within a growing parenteral nutrition market. Its demand hinges on hospital practices, patient demographics, and regulatory factors. Estimated revenues for targeted manufacturers range broadly but can reach hundreds of millions annually with successful market penetration. Competitive pressure and regulatory compliance remain critical success factors.

---

Key Takeaways

• The global parenteral nutrition market is expanding at around 6% annually, with amino acid solutions like AMINOSYN II representing a significant segment.
• Demand is driven by rising malnutrition cases and ICU patient populations.
• Market competition includes several large pharmaceutical companies employing pricing and formulary strategies to expand adoption.
• Revenue potential is sizable but sensitive to pricing, reimbursement policies, and competition.
• Supply chain stability, clinical evidence, and hospital relationships are critical to sustaining growth.

---

FAQs

1. What factors influence the pricing of AMINOSYN II?
Pricing depends on manufacturing costs, competition, hospital procurement strategies, and reimbursement policies. Reimbursement rates and formulary placements significantly impact net revenue.

2. How does regulatory approval affect market trajectory?
Regulatory approval in major markets enables wider distribution and trust, directly influencing sales growth and pricing power.

3. Is there room for innovation within amino acid infusion solutions?
Yes. Developments include formulations with enhanced stability, tailored amino acid profiles, or additives targeting specific patient needs. These innovations can open new market segments.

4. How does hospital adoption impact sales?
Hospitals’ formulary preferences, clinical guidelines, and procurement processes determine the institutional demand, which directly drives sales volume.

5. What are the main risks facing AMINOSYN II’s market growth?
Supply chain issues, regulatory delays, rising competition, and adoption barriers in hospitals can impede growth.

---

References

1. MarketsandMarkets. Parenteral nutrition market size and forecast. 2022.